Steven Shak Sells 5,000 Shares of Genomic Health Inc. (GHDX) Stock
Genomic Health Inc. (NASDAQ:GHDX) insider Steven Shak sold 5,000 shares of Genomic Health stock in a transaction dated Tuesday, October 11th. The stock was sold at an average price of $30.39, for a total value of $151,950.00. Following the sale, the insider now owns 332,207 shares of the company’s stock, valued at approximately $10,095,770.73. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Steven Shak also recently made the following trade(s):
- On Tuesday, September 13th, Steven Shak sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $26.83, for a total value of $134,150.00.
- On Tuesday, August 23rd, Steven Shak sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $27.24, for a total value of $136,200.00.
- On Tuesday, July 19th, Steven Shak sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $27.42, for a total value of $137,100.00.
Genomic Health Inc. (NASDAQ:GHDX) traded down 5.15% during trading on Wednesday, reaching $28.91. The company had a trading volume of 215,779 shares. The stock has a 50 day moving average of $28.21 and a 200-day moving average of $27.28. Genomic Health Inc. has a 12 month low of $20.05 and a 12 month high of $35.79. The company’s market capitalization is $964.03 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/steven-shak-sells-5000-shares-of-genomic-health-inc-ghdx-stock.html
Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.18) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.18). Genomic Health had a negative return on equity of 21.02% and a negative net margin of 8.84%. The firm earned $81.97 million during the quarter, compared to analysts’ expectations of $81.27 million. During the same period last year, the firm posted ($0.29) EPS. The business’s revenue was up 16.1% on a year-over-year basis. Equities research analysts expect that Genomic Health Inc. will post ($0.47) EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in GHDX. Bank of Montreal Can acquired a new stake in Genomic Health during the second quarter worth $187,000. Royal Bank of Canada boosted its stake in Genomic Health by 6,543.0% in the first quarter. Royal Bank of Canada now owns 8,503 shares of the company’s stock worth $210,000 after buying an additional 8,375 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Genomic Health during the second quarter worth $270,000. American International Group Inc. boosted its stake in Genomic Health by 3.2% in the second quarter. American International Group Inc. now owns 10,753 shares of the company’s stock worth $278,000 after buying an additional 334 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Genomic Health by 3.0% in the second quarter. Nationwide Fund Advisors now owns 11,932 shares of the company’s stock worth $309,000 after buying an additional 351 shares in the last quarter. 88.92% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have issued reports on GHDX shares. Leerink Swann reissued a “buy” rating on shares of Genomic Health in a research note on Tuesday, June 21st. Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, July 5th. Bank of America Corp. set a $28.00 price target on Genomic Health and gave the stock a “sell” rating in a research note on Wednesday, August 3rd. Canaccord Genuity reissued a “buy” rating and issued a $38.00 price target on shares of Genomic Health in a research note on Friday, August 5th. Finally, Jefferies Group raised their price target on Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, August 17th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $32.50.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.